NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
72.90 -0.35 (-0.48%) GOLD FUTURES
2,347.00 -0.40 (-0.02%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,241.14 +1,186.82 (+2.20%)
Johnson & Johnson (JNJ)
After hours:
| Previous close | 147.74 |
| Open | 147.48 |
| Bid | 147.64 x 800 |
| Ask | 148.00 x 800 |
| Day's range | 146.19 - 148.31 |
| 52-week range | 143.13 - 175.97 |
| Volume | |
| Avg. volume | 7,680,042 |
| Market cap | 355.707B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 21.93 |
| EPS (TTM) | 6.74 |
| Earnings date | 17 Jul 2024 |
| Forward dividend & yield | 4.96 (3.36%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | 172.16 |
Business WireJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J., June 04, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 17th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s execut
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
BenzingaJohnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients
Monday, Johnson & Johnson (NYSE:JNJ) announced longer-term data from Phase 1/2 MajesTEC-1 study of Tecvayli (teclistamab-cqyv) showing deep and durable responses in patients with relapsed or refractory multiple myeloma (RRMM). Results from the MajesTEC-1 study show that, at a median follow-up of 30.4 months, patients treated with Tecvayli at the recommended Phase 2 dose demonstrated an overall response rate (ORR) of 63%, with responses continuing to deepen and 46% of patients achieving a complet
